- Home
- TIL vs MNOV Comparison
TIL vs MNOV Comparison
Compare TIL & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | MNOV |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.7M | 72.7M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | TIL | MNOV |
|---|---|---|
| Price | $11.40 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $100.67 | $7.00 |
| AVG Volume (30 Days) | 62.3K | ★ 91.6K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.69 | $1.13 |
| 52 Week High | $42.79 | $2.24 |
Technical Indicators
Market Signals| Indicator | TIL | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 44.81 |
| Support Level | $10.72 | $1.48 |
| Resistance Level | $11.85 | $1.51 |
| Average True Range (ATR) | 0.60 | 0.05 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 60.52 | 7.69 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.